Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Firms / A•• A••••• F••• G•• L••

A•• A••••• F••• G•• L••

Institutional venture firmBoston, MAa•••••••••.comSEC venture capital fund adviser

Aiming to overcome technical and funding barriers in antibiotic development and ensuring a sustainable pipeline of new antibiotics to fight superbugs.

venture manager, reported GAV $977M across 2 vehicles

Importance
30
moderate
Active deployment
0
low
Emerging
0
low
Completeness
69
high
Freshness
99
high
Research priority
5
low
Identity and regulatory footprint
Headquarters
Boston, MAadviserinfo.sec.gov
Office address
225 FRANKLIN STREET, SUITE 1750, Boston, MA, 02110adviserinfo.sec.gov
Business phone
617-850-2876adviserinfo.sec.gov
SEC adviser type
exempt reporting adviseradviserinfo.sec.gov
SEC exemption claimed
venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
Latest Form ADV
Mar 31, 2026
Private funds reported
2 (2 venture capital funds)adviserinfo.sec.gov
Private fund gross assets
$977Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
business phone
617-850-2876adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
2 observed deals
Stated (the firm’s website)
Sectors
biotech, climate
Stages
not stated or not yet read
Geography
japan
Check size
not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors
Biotechnology 100%
lead rate n/afollow-on rate n/anew logos, 12 months 0
Funds and vehicles
2 reported
VehicleTypeVintageLifecycleReported GAVOwnersForm D soldLatest Form D
A•• A••••• F••• L•••FundunknownUnknown$725M
Mar 27, 2024
12$0
of $1.3B
Dec 14, 2020
A•• A••••• F•••• S•••FundunknownUnknown$252M
Mar 27, 2024
14$0
of $1.3B
Dec 14, 2020
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
17 current, 3 departed
D•••• C••••••••• H•••••••
Chief Compliance Officer, General Counsel And Chief Operating Officer · since Nov 1, 2022
Platform and operations
D•••• C••••••••• H•••••••
Chief Compliance Officer, General Counsel And Chief Operating Officer · since Nov 1, 2022
Platform and operations
D•••• H•••••••
Chief Legal Officer, Chief Compliance Officer, Chief Operating Officer
Platform and operations
3 departed (kept with end dates)
Investments on record
2 edges, 2 companies, 2 partner-attributed
CompanyRoundRolePartnerRound sizeThis investorDateSource
V•••••• B••••••••• I•••board seatunknown · boardM••••• H•••••••• (strongly supported)unknownunknownAug 5, 2024Inference SEC EDGAR Form D data sets (quarterly)
E•••• T••••••••• I•••board seatunknown · boardM••••• H•••••••• (strongly supported)unknownunknownJun 26, 2024Inference SEC EDGAR Form D data sets (quarterly)
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
0 relationships from shared deals, counted for the whole firm
No co-investor relationship yet: these are derived only from rounds and portfolio listings the graph has seen both investors on.
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
11 dated events
  1. Sep 16, 2026
    D•••• H••••••• (Chief Legal Officer, Chief Compliance Officer, Chief Operating Officer) no longer on the team page of A•• A••••• F••• G•• L••
  2. Mar 30, 2023
    E••••• M••••• (Head Of Finance And Operations) no longer on Schedule A of A•• A••••• F••• G•• L••
  3. Dec 1, 2022
    J••• W•••••• V•••••• joined Schedule A of A•• A••••• F••• G•• L•• as Finance Director
  4. Nov 1, 2022
    D•••• C••••••••• H••••••• joined Schedule A of A•• A••••• F••• G•• L•• as Chief Compliance Officer, General Counsel And Chief Operating Officer
  5. Aug 1, 2021
    M••••• H•••••••• joined Schedule A of A•• A••••• F••• G•• L•• as Chief Investment Officer
  6. Jul 1, 2021
    E••••• M••••• joined Schedule A of A•• A••••• F••• G•• L•• as Head Of Finance And Operations
  7. Apr 30, 2021
    M••••• B••• (Interim Chief Executive Officer) no longer on Schedule A of A•• A••••• F••• G•• L••
  8. Mar 1, 2021
    H•••• B••••••• S•••••• joined Schedule A of A•• A••••• F••• G•• L•• as Chief Executive Officer
  9. Feb 12, 2021
    A•• A••••• F••• G•• L•• first filed Form ADV (ERA, venture capital fund adviser exemption)
  10. Feb 12, 2021
    A•• A••••• F••• L••• first reported on Form ADV by A•• A••••• F••• G•• L•• (Venture Capital Fund), GAV $725,252,500
  11. Feb 12, 2021
    A•• A••••• F•••• S••• first reported on Form ADV by A•• A••••• F••• G•• L•• (Venture Capital Fund), GAV $251,620,000
Classification history
  1. Sep 12, 2026
    Institutional venture firm (confirmed, 95%, cls-1)
    venture manager, reported GAV $977M across 2 vehicles
Evidence
51 observations from 4 sources
Every observation behind this profile, with its source, date and class
FactValueEffectiveClassSource
Why admittedvc_exemption,vc_funds_reportedMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
SEC exemption claimedventure_capital_fund_adviserMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
SEC exemption claimedventure_capital_fund_adviserMar 27, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
SEC adviser typeexempt_reporting_adviserMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
SEC adviser typeexempt_reporting_adviserMar 27, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
First Form ADV filing2021-02-12Mar 27, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Adv history loadedadv-hist-1Sep 12, 2026FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Latest Form ADV filing2026-03-31Mar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Latest Form ADV filing2024-03-27Mar 27, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
SEC statusERA - ActiveMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
SEC status effective2021-02-12Mar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Venture share of reported funds1Mar 27, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Business phone617-850-2876Mar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Business phone617-850-2876Mar 27, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Contact page urlhttps://a•••••••••.com/
contact page linked from the home page
Sep 16, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
DescriptionAiming to overcome technical and funding barriers in antibiotic development and ensuring a sustainable pipeline of new antibiotics to fight superbugs.
meta description
Sep 16, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
DescriptionAiming to overcome technical and funding barriers in antibiotic development and ensuring a sustainable pipeline of new antibiotics to fight superbugs.
meta description
Sep 15, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
HeadquartersBoston, MAMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
HeadquartersBoston, MAMar 27, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Office address225 FRANKLIN STREET, SUITE 1750, Boston, MA, 02110Mar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Office address225 FRANKLIN STREET, SUITE 1750, Boston, MA, 02110Mar 27, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Legal formLimited Liability CompanyMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Legal formLimited Liability CompanyMar 27, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Portfolio pagehttps://a•••••••••.com/
0 entries read
Sep 16, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Portfolio pagehttps://a•••••••••.com/
0 entries read
Sep 15, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Private funds reported2Mar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Private funds reported2Mar 27, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Private fund gross assets (reported)$977MMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Private fund gross assets (reported)$977MMar 27, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Schedule a diffsadiff-1Mar 31, 2026FactIAPD Form ADV Part 1 PDF per firm (current filing, Schedule D 7.B.(1) and Schedule A)
Stated geographyjapan
geography words on the home page
Sep 16, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Stated geographyjapan
geography words on the home page
Sep 15, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Stated sectorsbiotech,climate
sector words on the home page
Sep 16, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Stated sectorsbiotech,climate
sector words on the home page
Sep 15, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Team pagehttps://a•••••••••.com/
9 name/title pairs read
Sep 16, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Team pagehttps://a•••••••••.com/
8 name/title pairs read
Sep 15, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Venture funds reported2Mar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Venture funds reported2Mar 27, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Websitehttps://a•••••••••.com/
re-picked from Schedule D 1.I by name
Sep 12, 2026FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Websitehttps://a•••••••••.com/Mar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Websitehttps://mastodon.social/@AMRActionFundMar 27, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Websitehttps://a•••••••••.com/Mar 27, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Site titleAntimicrobial Resistance Research & Development - AMR A••••• Fund
title tag
Sep 16, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Site titleAntimicrobial Resistance Research & Development - AMR A••••• Fund
title tag
Sep 15, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)